{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:45:22Z","timestamp":1792079122992,"version":"4.4.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Laser therapy is increasingly used to treat genitourinary syndrome of menopause (GSM) in breast cancer survivors, but sham-controlled evidence of benefit remains limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To evaluate 12-month efficacy and safety of fractional carbon dioxide (CO\n 2<\/jats:sub>\n ) laser therapy (CLT) vs sham laser therapy (SLT) for GSM in breast cancer survivors receiving aromatase inhibitors.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This is a secondary analysis of a single-center, double-blind, sham-controlled randomized clinical trial conducted at a tertiary academic hospital in Spain. Participants included breast cancer survivors with GSM and dyspareunia receiving aromatase inhibitors, recruited from October 30, 2020, to September 1, 2021. Participants were followed up for 12 months. Data were analyzed from December 1, 2024, to June 30, 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Five monthly sessions of CLT or SLT plus first-line nonhormonal therapy (FLT), including vaginal moisturizers and vibrators.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the between-group difference in change in Female Sexual Function Index (FSFI) score. Secondary outcomes included rate of sexual activity, dyspareunia, Spanish Body Image Scale, quality of life (12-Item Short Form Health Survey), Vaginal Health Index, objective parameters (pH, vaginal maturation index, epithelial measures), serum estradiol level, FLT adherence, and adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 84 randomized participants (mean [SD] age, 53.8 [8.8] years), 67 completed the 12-month follow-up (CLT, 32; SLT, 35). The CLT group did not differ from the SLT group in FSFI score change from baseline to 12 months (difference, CLT vs SLT, \u22120.69 [95% CI, \u22123.58 to 2.20];\n P<\/jats:italic>\n \u2009=\u2009.64), nor in any secondary outcome. Across the full sample, significant improvements from baseline to 12 months were observed in FSFI score (18.9 to 23.0; mean difference, 4.5 [95% CI, 3.1-5.9];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), dyspareunia (mean difference, \u22123.7 [95% CI, \u22124.4 to \u22123.0];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), Spanish Body Image Scale (mean difference, \u22123.9 [95% CI, \u22125.1 to \u22122.8];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and Vaginal Health Index (mean difference, 4.2 [95% CI, 3.1-5.2];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Sexual activity increased among 57 of 67 participants (85.1%; odds ratio, 2.35 [95% CI, 1.23-4.50];\n P<\/jats:italic>\n \u2009=\u2009.009). Improvements were found in pH (mean difference, \u22120.5 [95% CI, \u22120.8 to \u22120.2];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and vaginal maturation index (mean difference, 19.0% [95% CI, 13.4%-24.5%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). FLT adherence was similar between groups. No severe adverse effects occurred.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of breast cancer survivors receiving aromatase inhibitors, vulvovaginal CLT provided no additional benefit for sexual or vaginal health at 12 months. Improvements in both groups likely reflected FLT adherence, trial participation, or contextual factors rather than laser efficacy. High-quality sham-controlled trials remain essential before routine implementation.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04619485<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.38937","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:35Z","timestamp":1792076435000},"page":"e2638937","source":"Crossref","is-referenced-by-count":0,"title":["Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors"],"prefix":"10.1001","volume":"9","author":[{"given":"S\u00f2nia","family":"Angl\u00e8s-Acedo","sequence":"first","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"Clinical Sexology Working Group, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Alonso","sequence":"additional","affiliation":[{"name":"Gynecology, Obstetrics and Neonatology Service, University Hospital Joan XXIII, Tarragona, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 Sanit\u00e0ria Pere Virgili, Tarragona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ribera-Torres","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"Clinical Sexology Working Group, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Mension","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Otero","sequence":"additional","affiliation":[{"name":"Unit of Biophysics and Bioengineering, Faculty of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Herranz-Diez","sequence":"additional","affiliation":[{"name":"Unit of Biophysics and Bioengineering, Faculty of Medicine, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Farr\u00e9","sequence":"additional","affiliation":[{"name":"Unit of Biophysics and Bioengineering, Faculty of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Castrejon","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Al\u00f2s","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camil","family":"Castelo-Branco","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"Clinical Sexology Working Group, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"6","key":"zoi261047r1","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/GME.0000000000001738","article-title":"Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy.","volume":"28","author":"Quick","year":"2021","journal-title":"Menopause"},{"issue":"9","key":"zoi261047r2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45495","article-title":"Vaginal laser treatment for the genitourinary syndrome of menopause in breast cancer survivors: a narrative review.","volume":"15","author":"Okui","year":"2023","journal-title":"Cureus"},{"key":"zoi261047r3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2147\/IJWH.S414509","article-title":"Genitourinary syndrome of menopause in breast cancer survivors: current perspectives on the role of laser therapy.","volume":"15","author":"Cucinella","year":"2023","journal-title":"Int J Womens Health"},{"issue":"4","key":"zoi261047r4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/13697137.2023.2225766","article-title":"Vaginal laser therapy for GSM\/VVA: where we stand now\u2014a review by the EUGA Working Group on Laser.","volume":"26","author":"Salvatore","year":"2023","journal-title":"Climacteric"},{"issue":"5","key":"zoi261047r5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jsxm.2020.02.013","article-title":"Laser-based devices for female genitourinary indications: position statements from the European Society for Sexual Medicine (ESSM).","volume":"17","author":"Romero-Otero","year":"2020","journal-title":"J Sex Med"},{"issue":"3","key":"zoi261047r6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00192-018-3830-0","article-title":"IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity.","volume":"30","author":"Shobeiri","year":"2019","journal-title":"Int Urogynecol J"},{"issue":"2","key":"zoi261047r7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/LGT.0000000000000462","article-title":"The clinical role of laser for vulvar and vaginal treatments in gynecology and female urology: an ICS\/ISSVD best practice consensus document.","volume":"23","author":"Preti","year":"2019","journal-title":"J Low Genit Tract Dis"},{"issue":"2","key":"zoi261047r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55697","article-title":"Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial.","volume":"6","author":"Mension","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"20","key":"zoi261047r10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"22","key":"zoi261047r11","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 statement: updated guideline for reporting randomized trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"key":"zoi261047r12","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1016\/j.jsxm.2022.03.389","article-title":"115 Sexual assessment in breast cancer survivors receiving aromatase inhibitors: are they interested on sexology consultation?","volume":"19","author":"Angl\u00e8s-Acedo","year":"2022","journal-title":"J Sex Med"},{"key":"zoi261047r13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/B978-0-443-29884-4.00008-X","article-title":"Ethical considerations with using placebo treatments and effects in clinical practice.","volume":"213","author":"Druart","year":"2025","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"zoi261047r14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/GME.0000000000001305","article-title":"The female sexual function index: reliability and validity in Spanish postmenopausal women.","volume":"26","author":"P\u00e9rez-Herrezuelo","year":"2019","journal-title":"Menopause"},{"issue":"1","key":"zoi261047r15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jsxm.2019.10.007","article-title":"Scoring and interpretation of the FSFI: what can be learned from 20 years of use?","volume":"17","author":"Meston","year":"2020","journal-title":"J Sex Med"},{"issue":"5","key":"zoi261047r17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/lsm.70027","article-title":"Efficacy of Erbium and CO2 genital laser treatment on genitourinary syndrome in female patients after breast cancer: a scoping review.","volume":"57","author":"Ferreira","year":"2025","journal-title":"Lasers Surg Med"},{"issue":"1","key":"zoi261047r18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/medicina59010132","article-title":"Emerging use of vaginal laser to treat genitourinary syndrome of menopause for breast cancer survivors: a review.","volume":"59","author":"Jugulyte","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"20","key":"zoi261047r19","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.3390\/jcm13206131","article-title":"Effect of vaginal laser and topical therapies on vulvovaginal atrophy symptoms in breast cancer patients: a systematic review and meta-analysis.","volume":"13","author":"Loczi","year":"2024","journal-title":"J Clin Med"},{"key":"zoi261047r20","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3332\/ecancer.2019.988","article-title":"A systematic review of laser therapy for vulvovaginal atrophy\/genitourinary syndrome of menopause in breast cancer survivors.","volume":"13","author":"Knight","year":"2019","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"zoi261047r21","doi-asserted-by":"publisher","first-page":"e556","DOI":"10.1016\/j.clbc.2019.04.007","article-title":"The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis.","volume":"19","author":"Jha","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"zoi261047r22","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00192-019-04051-3","article-title":"Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. hope or hype?","volume":"30","author":"Tranoulis","year":"2019","journal-title":"Int Urogynecol J"},{"issue":"7","key":"zoi261047r23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/cancers17071241","article-title":"CO2 Laser therapy for genitourinary syndrome of menopause in women with breast cancer: a randomized, sham-controlled trial.","volume":"17","author":"Jaber","year":"2025","journal-title":"Cancers (Basel)"},{"key":"zoi261047r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2022.08.013","article-title":"Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial.","volume":"167","author":"Gold","year":"2023","journal-title":"Maturitas"},{"issue":"14","key":"zoi261047r25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2021.14892","article-title":"Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial.","volume":"326","author":"Li","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"zoi261047r26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/aogs.14353","article-title":"The evidence behind the use of laser for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-the-art review.","volume":"101","author":"Mortensen","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"5","key":"zoi261047r27","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1016\/j.clbc.2021.01.006","article-title":"Microablative fractional CO2 laser for vulvovaginal atrophy in women with a history of breast cancer: a pilot study at 4-week follow-up.","volume":"21","author":"Salvatore","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"zoi261047r28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s10103-018-2471-3","article-title":"Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects.","volume":"33","author":"Becorpi","year":"2018","journal-title":"Lasers Med Sci"},{"issue":"1","key":"zoi261047r29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-019-05384-9","article-title":"Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study.","volume":"178","author":"Pearson","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"zoi261047r30","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00404-023-07323-y","article-title":"Safety and efficacy of non-ablative CO2 laser treatment of vulvo-vaginal atrophy in women with history of breast cancer.","volume":"309","author":"Lami","year":"2024","journal-title":"Arch Gynecol Obstet"},{"issue":"8","key":"zoi261047r31","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00520-019-05211-3","article-title":"Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors.","volume":"28","author":"Quick","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"zoi261047r32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10549-021-06226-3","article-title":"Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up.","volume":"188","author":"Veron","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"zoi261047r33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/GME.0000000000001727","article-title":"The short-term efficacy and safety of fractional CO2 laser therapy for vulvovaginal symptoms in menopause, breast cancer, and lichen sclerosus.","volume":"28","author":"Gardner","year":"2021","journal-title":"Menopause"},{"issue":"12","key":"zoi261047r34","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/GME.0000000000002274","article-title":"CO2 laser, radiofrequency, and promestriene in the treatment of genitourinary syndrome of menopause in breast cancer survivors: a histomorphometric evaluation of the vulvar vestibule.","volume":"30","author":"Fernandes","year":"2023","journal-title":"Menopause"},{"key":"zoi261047r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.108155","article-title":"Clinical and histomorphometric evaluation of the vagina following treatment with CO2 laser, radiofrequency, and promestriene for genitourinary syndrome of menopause in breast cancer survivors on adjuvant therapy.","volume":"191","author":"Cantarelli","year":"2025","journal-title":"Maturitas"},{"issue":"9","key":"zoi261047r36","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.","volume":"27","author":"The NAMS 2020 GSM Position Statement Editorial Panel","year":"2020","journal-title":"Menopause"},{"issue":"3","key":"zoi261047r37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajog.2024.10.054","article-title":"Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks.","volume":"232","author":"Beste","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"zoi261047r8","unstructured":"FDA warns against use of energy-based devices to perform vaginal \u2019rejuvenation\u2019 or vaginal cosmetic procedures: FDA safety communication. US Food and Drug Administration. August 13, 2018. Accessed January 10, 2023. https:\/\/www.iuga.org\/news\/news\/fda-warns-against-use-of-energy-based-devices-to-perform-vaginal-rejuvenation-or-vaginal-cosmetic-procedures-fda-safety-communication"},{"key":"zoi261047r16","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. National Cancer Institute. 2017. Accessed January 10, 2023. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855354\/anglsacedo_2026_oi_261047_1791405265.35333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:36Z","timestamp":1792076436000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855354"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.38937","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}